



# Coronavirus: Employer Town Hall

October 13, 2020 | 5:00 pm ET

## *Employer Readiness for COVID-19 Vaccine*

## Moderators & participating panelists



Michael Thompson  
President & CEO  
National Alliance of Healthcare  
Purchaser Coalitions



Mohannad Kusti, MD  
Regional Medical Director for Pivot  
Onsite Innovations  
Medical Director for PBGH Coalition

## Panelists

- **Scott Conard, MD**  
Converging Health
- **Andrea Dowdy, MD**  
State of Tennessee
- **James Gelfand**  
The ERISA Industry Committee  
(ERIC)
- **Arnie Joseph**  
Chroma Health

# Vaccination Update – October, 2020

- 44 Vaccines in clinical trials on humans
- At least 92 preclinical vaccines are under investigation in animals
- 4 Vaccines are approved for limited use in other parts of world
- 5 Vaccines in U.S. Phase 3 Trials

## 4 Vaccines apparently approved for limited use in other parts of world

### 1. CanSino Biologics:

- Running Phase 3 trials in a number of countries, including Saudi Arabia, Pakistan and Russia
- Subjects will undergo for at least six months.
- Chinese health official has publicly pledged that an effective coronavirus vaccine will be available by the end of the year.

### 2. Gamaleya Research Institute (part of Russia's Ministry of Health)

- Putin announced that Russian regulator had approved the vaccine, renamed Sputnik V, before Phase 3 trials had begun.
- Russia later clarified approval was “conditional registration certificate” (depend on positive results from Phase 3 trials)
- Russia negotiated agreements to supply the vaccine to countries including Brazil, Mexico and India.

### 3. Wuhan Institute of Biological Products developed Sinopharm.

- Launched Phase 3 trials in the United Arab Emirates, Peru and Morocco, some participants experience fevers & other side effects.
- The government gave its approval to inject hundreds of thousands of people with its two experimental vaccines.
- On Sept. 14, the U.A.E. gave emergency approval for Sinopharm's vaccine to use on health care workers.

### 4. Chinese company Sinovac Biotech is testing a vaccine called CoronaVac.

- Launched a Phase 3 trial in Brazil, Indonesia, and Turkey, China gave vaccine an emergency approval for limited use in July.
- Agreement to supply Indonesia with at least 40 million doses by March 2021.
- Planning on worldwide distribution of the vaccine in early 2021 — including the United States.

# 5 Vaccines in Phase 3 Clinical Trials in U.S.

1. Moderna (\$1 billion US Support) – In July, Moderna lost a patent dispute over some of their vaccine technology.
  - It may take till the end of 2020 or early 2021 to reach the necessary numbers.
2. BioNTech with Pfizer, and Fosun Pharma: (\$1.9 billion contract with US for 100 Million doses delivered by December 2020 and the option to acquire 500 million more doses).
  - Pfizer expects to manufacture over 1.3 billion doses of their vaccine worldwide by the end of 2021.
3. Johnson & Johnson developed a vaccine (U.S. to pay \$1 billion for 100 million doses if the vaccine is approved).
  - The company is aiming for production of at least a billion doses in 2021.
4. AstraZeneca and the University of Oxford: (\$1.2 billion in U.S. support).
  - On Sept. 6, halted global trials to investigate one volunteer, who developed a form of inflammation called transverse myelitis. Within a week, the trials resumed.
  - As of now, the United States is still keeping its trial on pause as the F.D.A. investigates.
5. Novavax: The Coalition for Epidemic Preparedness Innovations (\$1.6 billion in U.S. support).
  1. Could potentially deliver results by the start of 2021. Expects to deliver 100 million doses for use in U.S. by the first quarter of 2021.

# CDC Covid-19 Vaccination Program Interim Playbook

- First detailed public guidance on how future vaccinations will be distributed in U.S. – 57 pages
- Focus on local “Jurisdictions” - plan for a phased approach
  - Phase I
    - focus on providing access to critical populations – first, health care personnel, immediately followed by high risk populations, and other essential workers
    - Identify a limited number of participating providers to be selected based on criteria outlined below.
    - Manage cold-supply chain requirements
  - Phase 2,
    - Broaden focus on “ensuring access to vaccine for critical populations who were not yet vaccinated as well as for the general population.”
    - Expand the network of providers able to administer vaccinations.
    - Work with stakeholders, including employers, to identify critical workers who may be able to access the vaccine before the general population (pp. 14-16).
  - Phase 3 – Steady state

# Covid-19 Vaccination will require a phased approach

Phase I	Phase II	Phase III
<p><b>Potentially Limited Supplies Available</b></p>	<p><b>Large Number of Doses Available</b></p>	<p><b>Continued Vaccination, Shift to Routine Strategy</b></p>
<ul style="list-style-type: none"> <li>• Supply may be constrained</li> <li>• Tight focus on vaccine administration</li> <li>• Administer vaccine in closed settings to priority populations:               <ul style="list-style-type: none"> <li>• 1-A Healthcare workers likely to be exposed</li> <li>• 1-B Other essential workers</li> <li>• 1-B Those most at risk of severe illness including those over age 65</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Likely sufficient supply to meet demand</li> <li>• Use a broad provider network to distribute vaccine               <ul style="list-style-type: none"> <li>• Healthcare settings</li> <li>• Commercial sector (eg Retail Rx)</li> <li>• Public health venues</li> </ul> </li> <li>• Expand beyond initial populations               <ul style="list-style-type: none"> <li>• Remainder of Phase I</li> <li>• Critical Populations</li> <li>• General Population</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Likely sufficient supply</li> <li>• Open access to vaccinations</li> <li>• Administer through additional private partner sites</li> <li>• Maintain public health sites where required</li> </ul>

# Potential employer readiness consideration

- Timing of approved and available vaccine
- Public health relationships
- Advocacy for priority workers
- Cost of vaccine
- Worker trust and readiness for vaccine
- Potential access to and distribution of vaccine (2 doses)
- Contingency planning
- Other

# Open Panel Discussion



**Michael Thompson**  
National Alliance of Healthcare  
Purchaser Coalitions



**Mohannad Kusti, MD**  
Regional Medical Director for Pivot  
Onsite Innovations  
Medical Director for PBGH Coalition



**Scott Conard, MD**  
Converging Health



**Andrea Dowdy**  
State of Tennessee



**James Gelfand**  
The ERISA Industry  
Committee (ERIC)



**Arnie Joseph**  
Chroma Health



## 2020 ANNUAL FORUM

Employers driving innovation, health and value

NOVEMBER 9 – 10

VIRTUAL EVENT

**Registration now open!**

Organizations participating include:

- American Academy of Family Physicians
- American Health Policy Institute
- Boeing
- City of Miami
- General Motors
- News Corp
- Rice University
- The Walt Disney Company
- ...And more!



### This Year's Topics

#### Health Benefits Strategy

- CEO Engagement in light of COVID-19
- Coalition Board Panel - Role of Employers and Coalitions in the "New Normal"
- Keynote Panel: A Conversation on Leading Change Together
- Moving from Low Value to High Value Care
- Managing Drug Value, MTM and Beyond
- Pain Management

#### Healthcare Value

- Advanced & Virtual Primary Care Go Mainstream
- Contracting & Connecting for Value
- Maternity Care in Crisis
- Personalizing the Patient's Journey
- Delivery and Payment Reform in the post COVID-19 Era

#### Innovation

- Innovative Practices to Mitigate "Shock" Claims
- Keynote: Race, Health & Equity
- Innovator Showcase
- Innovations in Population Health